These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 8653534)
1. Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects. Drent ML; Popp-Snijders C; Adèr HJ; Jansen JB; van der Veen EA Obes Res; 1995 Nov; 3(6):573-81. PubMed ID: 8653534 [TBL] [Abstract][Full Text] [Related]
2. Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study. Froehlich F; Hartmann D; Guezelhan C; Gonvers JJ; Jansen JB; Fried M Dig Dis Sci; 1996 Dec; 41(12):2404-8. PubMed ID: 9011450 [TBL] [Abstract][Full Text] [Related]
3. Long-term effects of lipase inhibition by orlistat on gastric emptying and orocecal transit time of a solid meal. Kocełak P; Zahorska-Markiewicz B; Jonderko K; Olszanecka-Glinianowicz M; Zak-Gołab A; Holecki M; Kamińska M; Szymszal M J Gastroenterol; 2008; 43(8):609-17. PubMed ID: 18709483 [TBL] [Abstract][Full Text] [Related]
4. First clinical studies with orlistat: a short review. Drent ML; van der Veen EA Obes Res; 1995 Nov; 3 Suppl 4():623S-625S. PubMed ID: 8697067 [TBL] [Abstract][Full Text] [Related]
5. Long-term inhibition of intestinal lipase by orlistat improves release of gut hormones increasing satiety in obese women. Olszanecka-Glinianowicz M; Dąbrowski P; Kocełak P; Janowska J; Smertka M; Jonderko K; Chudek J Pharmacol Rep; 2013; 65(3):666-71. PubMed ID: 23950589 [TBL] [Abstract][Full Text] [Related]
6. [Pharmacological therapy of obesity]. Pagotto U; Vanuzzo D; Vicennati V; Pasquali R G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755 [TBL] [Abstract][Full Text] [Related]
7. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Finer N; James WP; Kopelman PG; Lean ME; Williams G Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623 [TBL] [Abstract][Full Text] [Related]
8. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. Davidson MH; Hauptman J; DiGirolamo M; Foreyt JP; Halsted CH; Heber D; Heimburger DC; Lucas CP; Robbins DC; Chung J; Heymsfield SB JAMA; 1999 Jan; 281(3):235-42. PubMed ID: 9918478 [TBL] [Abstract][Full Text] [Related]
9. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Karhunen L; Franssila-Kallunki A; Rissanen P; Valve R; Kolehmainen M; Rissanen A; Uusitupa M Int J Obes Relat Metab Disord; 2000 Dec; 24(12):1567-72. PubMed ID: 11126207 [TBL] [Abstract][Full Text] [Related]
10. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632 [TBL] [Abstract][Full Text] [Related]
11. Lipase inhibition: a novel concept in the treatment of obesity. Drent ML; van der Veen EA Int J Obes Relat Metab Disord; 1993 Apr; 17(4):241-4. PubMed ID: 8387973 [TBL] [Abstract][Full Text] [Related]
12. Influences of fat restriction and lipase inhibition on gastric emptying in obesity. Mathus-Vliegen EM; van Ierland-van Leeuwen ML; Bennink RJ Int J Obes (Lond); 2006 Aug; 30(8):1203-10. PubMed ID: 16462818 [TBL] [Abstract][Full Text] [Related]
13. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Damci T; Yalin S; Balci H; Osar Z; Korugan U; Ozyazar M; Ilkova H Diabetes Care; 2004 May; 27(5):1077-80. PubMed ID: 15111524 [TBL] [Abstract][Full Text] [Related]
14. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Muls E; Kolanowski J; Scheen A; Van Gaal L; Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595 [TBL] [Abstract][Full Text] [Related]
15. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Heymsfield SB; Segal KR; Hauptman J; Lucas CP; Boldrin MN; Rissanen A; Wilding JP; Sjöström L Arch Intern Med; 2000 May; 160(9):1321-6. PubMed ID: 10809036 [TBL] [Abstract][Full Text] [Related]
16. A one-year trial to assess the value of orlistat in the management of obesity. James WP; Avenell A; Broom J; Whitehead J Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S24-30. PubMed ID: 9225173 [TBL] [Abstract][Full Text] [Related]
17. Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes. O'Donovan D; Horowitz M; Russo A; Feinle-Bisset C; Murolo N; Gentilcore D; Wishart JM; Morris HA; Jones KL Diabetologia; 2004 Dec; 47(12):2208-14. PubMed ID: 15662558 [TBL] [Abstract][Full Text] [Related]
18. Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects. O'Donovan D; Feinle-Bisset C; Wishart J; Horowitz M Br J Nutr; 2003 Nov; 90(5):849-52. PubMed ID: 14667178 [TBL] [Abstract][Full Text] [Related]
19. Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Tiikkainen M; Bergholm R; Rissanen A; Aro A; Salminen I; Tamminen M; Teramo K; Yki-Järvinen H Am J Clin Nutr; 2004 Jan; 79(1):22-30. PubMed ID: 14684393 [TBL] [Abstract][Full Text] [Related]
20. Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus. Tan KC; Tso AW; Tam SC; Pang RW; Lam KS Diabet Med; 2002 Nov; 19(11):944-8. PubMed ID: 12421432 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]